cyc 202 has been researched along with bs-181 in 6 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (bs-181) | Trials (bs-181) | Recent Studies (post-2010) (bs-181) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 20 | 0 | 17 |
| Protein | Taxonomy | cyc 202 (IC50) | bs-181 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 1.79 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 8.1 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 1.8 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 1.1933 | |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | 4.2 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0662 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 2.7233 | |
| Cyclin-H | Homo sapiens (human) | 0.0775 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.134 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 3.35 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aboagye, EO; Ali, S; Alikian, M; Barbazanges, M; Barrett, AG; Blum, A; Brackow, J; Coombes, RC; Freemont, PS; Fuchter, MJ; Hazel, P; Heathcote, DA; Jogalekar, AS; Kanneganti, SK; Kroll, SH; Liotta, DC; Pace, RD; Patel, H; Periyasamy, M; Scheiper, B; Siwicka, A; Snyder, JP | 1 |
| Baltus, CB; Bazgier, V; Berka, K; Jorda, R; Kryštof, V; Marot, C; Prié, G; Viaud-Massuard, MC | 1 |
| Havlíček, L; Jorda, R; Kryštof, V; Pospíšil, T; Skrášková, Z; Strnad, M; Šturc, A; Vymětalová, L | 1 |
| de Dios, A; Lallena, MJ; Sánchez-Martínez, C; Sanfeliciano, SG | 1 |
| Diab, S; Wang, S; Yu, M | 1 |
| Albert, T; Antrecht, C; Baumgart, K; Eickhoff, J; Kelso, TW; Klebl, B; Lemcke, S; Meisterernst, M | 1 |
2 review(s) available for cyc 202 and bs-181
| Article | Year |
|---|---|
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinases; Drug Discovery; Humans; Indoles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Transcription Factors | 2019 |
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Humans; Neoplasms; Protein Kinase Inhibitors | 2020 |
4 other study(ies) available for cyc 202 and bs-181
| Article | Year |
|---|---|
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Female; Humans; In Vitro Techniques; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Phosphorylation; Protein Binding; Pyrazoles; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Heterocyclic Compounds; Humans; Indoles; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship | 2016 |
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; G2 Phase; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2016 |
Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; HEK293 Cells; HeLa Cells; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; RNA Polymerase II; RNA, Messenger; Roscovitine; Triazines | 2014 |